Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.51 |
| ▸ | SMO | Q99835 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.42 |
| ▸ | EGLN1 | Q9GZT9 | 3/20 | 0.41 |
| ▸ | TTK | P33981 | 1/20 | 0.41 |
| ▸ | HPGDS | O60760 | 2/20 | 0.39 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.39 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.39 |
| ▸ | DEGS1 | O15121 | 1/20 | 0.38 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.38 |
| ▸ | IDH1 | O75874 | 1/20 | 0.38 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.37 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13534631 | 0.91 | GPR119 (0.62) | GPR119SMOKCNH2EGLN1TTK | |
| SCHEMBL13534676 | 0.91 | GPR119 (0.44) | GPR119SMOEGLN1HPGDSDGAT1 | |
| SCHEMBL2394461 | 0.87 | GPR119 (0.47) | GPR119KCNH2TTKDGAT1CHRM4 | |
| SCHEMBL2393744 | 0.87 | GPR119 (0.47) | GPR119KCNH2TTKDGAT1CHRM4 | |
| SCHEMBL11918149 | 0.87 | GPR119 (0.39) | GPR119SMODGAT1CHRM4DEGS1 | |
| SCHEMBL1296068 | 0.85 | GPR119 (0.49) | GPR119KCNH2DGAT1CHRM4DEGS1 | |
| SCHEMBL1296307 | 0.84 | GPR119 (0.48) | GPR119DGAT1CHRM4DEGS1 | |
| SCHEMBL2391566 | 0.84 | GPR119 (0.52) | GPR119KCNH2EGLN1HPGDS | |
| SCHEMBL2391570 | 0.84 | GPR119 (0.52) | GPR119KCNH2EGLN1HPGDS | |
| SCHEMBL12103991 | 0.83 | GPR119 (0.47) | GPR119DGAT1CHRM4DEGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2321308-B9 | PIPERIDINE GPCR AGONISTS | PROSIDION LTD (GB) | 2012-08-08 | — | — | EP | claimed |
| EP-2321308-B1 | PIPERIDINE GPCR AGONISTS | PROSIDION LTD (GB) | 2012-05-09 | — | — | EP | claimed |
| EP-2321308-B9 | PIPERIDINE GPCR AGONISTS | PROSIDION LTD (GB) | 2012-08-08 | — | — | EP | disclosed |
| EP-2321308-B1 | PIPERIDINE GPCR AGONISTS | PROSIDION LTD (GB) | 2012-05-09 | — | — | EP | disclosed |
| US-20110230507-A1 | Piperidine GPCR Agonists | PROSIDION LIMITED (GB) | 2011-09-22 | — | — | US | disclosed |
| US-20110230507-A1 | Piperidine GPCR Agonists | PROSIDION LIMITED (GB) | 2011-09-22 | — | — | US | disclosed |
| WO-2010004344-A1 | PIPERIDINE GPCR AGONISTS | PROSIDION LIMITED (GB) | 2010-01-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110230507-A1 | Piperidine GPCR Agonists | GPR119, GPR27, GLP1R | GPR119 1/4885SMO 605/4885KCNH2 1120/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.